Company profile
VTV THERAPEUTICS INC.
NASDAQ:VTVTBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| CADISEGLIATIN | phase3 | — | 4 | active |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (14)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT02916056 | phase3 | terminated | 2016-12-01 | 2018-06-01 | vTv Therapeutics | 2-Year Extension Study of Azeliragon in Subjects With Alzheimer's Disease (STEADFAST Extension) |
| NCT01474083 | phase1_2 | completed | 2011-11-01 | 2012-08-01 | vTv Therapeutics | A 6 Week Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of GK1-399 in Type 2 Diabetes |
| NCT01548430 | phase1 | completed | 2011-10-01 | 2013-02-01 | vTv Therapeutics | A Safety Study of TTP4000 in Subjects With Alzheimer's Disease |
| NCT01665352 | phase2 | completed | 2012-08-01 | 2013-05-01 | vTv Therapeutics | A Study to Evaluate Safety and Efficacy of TTP054 for 12 Weeks in Subjects With Type 2 Diabetes |
| NCT02653599 | phase2 | completed | 2015-12-01 | 2016-11-01 | vTv Therapeutics | A Study to Evaluate Safety and Efficacy of TTP273 for 12 Weeks in Subjects With Type 2 Diabetes |
FDA applications (0)
No records yet.